Inhibrx Biosciences, Inc.

Stage 2 · Advancing · week 8

As of Oct 22, 2026, Inhibrx Biosciences is in Stage 2, the uptrend phase, now in week 8 (since Aug 28, 2026). It closed at $97.10, 31.5% below its 52-week high and above its 200-day average, which is rising.

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. More about the company

$97.10

-1.11% today

$1.4B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is INBX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2024-05-29 → 2026-10-22

S? 41w

S4 14w

S2 29w

S3 11w

S2 12w

2024-05-292026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 41w → S4 14w → S1 3w → S2 29w → S3 11w → S2 12w → S3 6w → S2 8w current

Total tracked: 124 weeks across 8 stage runs.

INBX among Biotechnology32nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…32	INBXInhibrx Biosciences, Inc.	Stage 2 · wk 8	97	−3.2%

vs 52W High

-31.5%

$28.36 lo$141.84 hi

31.5% below 52W high, far from high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 8

1w13w26w

Week 8, early Stage 2

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

5.7%

200 DMA: $91.90 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.85x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-3.2%

+19.1%

-19.0%

YTD

+29.4%

+158.8%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S2

Wk 8 · Vol 0.85x

2026-10-21S2

Wk 8 · Vol 0.73x

2026-10-20S2

Wk 8 · Vol 0.75x

2026-10-19S2

Wk 8 · Vol 0.52x

2026-10-16S2

Wk 7 · Vol 0.49x

2026-10-15S2

Wk 7 · Vol 0.76x

2026-10-14S2

Wk 7 · Vol 0.83x

2026-10-13S2

Wk 7 · Vol 0.92x

2026-10-12S2

Wk 7 · Vol 0.74x

2026-10-09S2

Wk 6 · Vol 0.29x

2026-10-08S2

Wk 6 · Vol 0.70x

2026-10-07S2

Wk 6 · Vol 0.76x

Moving averages & range

50 DMA

$103.87

200 DMA

$91.90

52W High

$141.84

52W Low

$28.36

5D Low

$89.79

Resistance levels (recent highs)

20d High

$104.83

60d High

$126.70

120d High

$141.84

250d High

$141.84

Next resistance

+8.0%

to 20d High

ROE

-1773.6%

Profit margin 0.0%

Dividend Yield

0.00%

P/B -27.0

Inhibrx Biosciences: quick answers

What stage is Inhibrx Biosciences in?

As of Oct 22, 2026, Inhibrx Biosciences (INBX) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 28, 2026 and is in week 8. What the four stages mean

Is Inhibrx Biosciences in an uptrend?

Yes. Inhibrx Biosciences is in a Stage 2 uptrend. It trades 5.7% above its 200-day average, which is rising.

How far is Inhibrx Biosciences from its 52-week high?

Inhibrx Biosciences closed at $97.10 on Oct 22, 2026, 31.5% below its 52-week high of $141.84. Its 52-week low is $28.36.

How has Inhibrx Biosciences performed over the past year?

As of Oct 22, 2026, Inhibrx Biosciences is up 158.8% over the past year and up 29.4% so far in 2026.

Which sector and industry is Inhibrx Biosciences in?

Inhibrx Biosciences is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.